{"classes":[{"categories":[{"measurements":[{"comment":"Standard Deviation was not reported in summary statistics because more than 50% of ADC concentrations at pre-dose were 0.","groupId":"OG000","spread":"NA","value":"0"}]}],"title":"ADC"},{"categories":[{"measurements":[{"comment":"Standard Deviation was not reported in summary statistics because more than 50% of TAb concentrations at pre-dose were 0.","groupId":"OG000","spread":"NA","value":"0"}]}],"title":"TAb"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"As per planned analysis, if more than 50% of PK concentrations were below the limit of quantification (i.e 0) at a given time point, standard deviation was not reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 1.25 mg/kg of body weight enfortumab vedotin by IV infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.","id":"OG000","title":"Enfortumab Vedotin 1.25 mg/kg"}],"paramType":"MEAN","populationDescription":"PKAS population.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: pre-dose","title":"PK of ADC , TAb in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 1","type":"PRIMARY","unitOfMeasure":"ug/mL"}